Reappraisal of Oncocytic Adenocarcinoma

Oncocytic adenocarcinoma (OC) of the salivary glands is a rare and controversial entity. It was recently reclassified as "salivary carcinoma NOS and emerging entities" in the 2022 WHO classification of head and neck tumors. The lack of specific molecular alterations and its potential affiliation with other salivary gland carcinomas, such as the oncocytic mucoepidermoid carcinomas (OMEC) or the oncocytic subtype of salivary duct carcinomas (OSDC) justified this reclassification. It is becoming essential to clarify the complex spectrum of potential diagnoses surrounding oncocytic tumors. The objective of this study was to explore the histologic features, as well as the immunohistochemical and molecular profiles, of cases previously diagnosed as OC or OMEC of the salivary glands. This study involved 28 cases of carcinomas with a predominantly oncocytic component. The sex distribution was equal. The median age was 59 years (range 10 to 89). Most of these cases originated from the parotid gland (25/28). The mean tumor size was 2.4 cm (range 0.5 to 6.5). Primary immuno-morphological and mutation/gene fusion profiles reclassified mainly (64.3%, 18/28). Most of them were reclassified in descending order as OSDC (8/18), OMEC (5/18), and OC (2/18). But 3 cases remained unclassified (3/18). The transcriptomic analysis found a proximity of their transcriptomic profile with the OMEC group and a distance from the OSDCs. These findings imply that OC is not distinct but represents oncocytic variants of other salivary carcinomas. It underscores the importance of thorough morphologic, immunohistochemical, and molecular examinations to accurately diagnose carcinomas with predominant oncocytic components in the salivary glands.

Authors

Institutions

Publication Details

Journal
The American Journal of Surgical Pathology
Published
2024-11-08
DOI
https://doi.org/10.1097/pas.0000000000002324
Citations
3
Primary Topic
Salivary Gland Tumors Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reappraisal of Oncocytic Adenocarcinoma

Marie‐Christine Rousselet, Michel Wassef, Olivier Mauvais, Ziyad Alsugair et al.
3 citations
The American Journal of Surgical Pathology
Salivary Gland Tumors Diagnosis and Treatment
1.72
article

Reappraisal of Oncocytic Adenocarcinoma

Marie‐Christine Rousselet, Michel Wassef, Olivier Mauvais, Ziyad Alsugair, Mihaela Onea, Jonathan Lopez, Nazim Benzerdjeb, Gaëlle Fromont, Charles Lépine, M. Fieux, Anne–Catherine Baglin, Odile Casiraghi, Philippe Céruse, Franck Monnien, Claire Castain, Emmanuelle Uro‐Coste, Anne Sudaka, Valérie Costes‐Martineau, Pierre Philouze, Philippe Delvenne, François Le Gall, H. M. Gilles, Françoise Descôtes, Lucas Vial
article en
3 citations

Abstract

Oncocytic adenocarcinoma (OC) of the salivary glands is a rare and controversial entity. It was recently reclassified as "salivary carcinoma NOS and emerging entities" in the 2022 WHO classification of head and neck tumors. The lack of specific molecular alterations and its potential affiliation with other salivary gland carcinomas, such as the oncocytic mucoepidermoid carcinomas (OMEC) or the oncocytic subtype of salivary duct carcinomas (OSDC) justified this reclassification. It is becoming essential to clarify the complex spectrum of potential diagnoses surrounding oncocytic tumors. The objective of this study was to explore the histologic features, as well as the immunohistochemical and molecular profiles, of cases previously diagnosed as OC or OMEC of the salivary glands. This study involved 28 cases of carcinomas with a predominantly oncocytic component. The sex distribution was equal. The median age was 59 years (range 10 to 89). Most of these cases originated from the parotid gland (25/28). The mean tumor size was 2.4 cm (range 0.5 to 6.5). Primary immuno-morphological and mutation/gene fusion profiles reclassified mainly (64.3%, 18/28). Most of them were reclassified in descending order as OSDC (8/18), OMEC (5/18), and OC (2/18). But 3 cases remained unclassified (3/18). The transcriptomic analysis found a proximity of their transcriptomic profile with the OMEC group and a distance from the OSDCs. These findings imply that OC is not distinct but represents oncocytic variants of other salivary carcinomas. It underscores the importance of thorough morphologic, immunohistochemical, and molecular examinations to accurately diagnose carcinomas with predominant oncocytic components in the salivary glands.

The American Journal of Surgical PathologyVol. 49(1)
Université Claude Bernard Lyon 1 (FR), Université de Tours (FR), Université de Bordeaux (FR), University of Liège (BE), Université Paris Cité (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Hospices Civils de Lyon (FR), Bordeaux Population Health (FR), Centre Hospitalier Universitaire d'Angers (FR), Hôpital Lariboisière (FR), Centre Antoine Lacassagne (FR), Centre Hospitalier Universitaire de Rennes (FR), Université de Strasbourg (FR), Université Grenoble Alpes (FR)
Good health and well-being
Openalex Percentile: Top 14%
Salivary Gland Tumors Diagnosis and Treatment
1.72
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.